|

BY101921 tablets Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Chengdu Baiyu Pharmaceutical Co., Ltd.1

Indications

  • Solid Tumor, Adult1
  • Cancer1

Other1 trial

A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.